Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 telaprevir combination study in previously treated genotype 1 chronic hepatitis C
NL-OMON30460Phase 2Not yet recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of telaprevir in hepatitis C virus infection (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Sustained virologic response at 24 weeks after treatment. Planned start Mar 2007; status: not yet recruiting.
02
Drugs
telaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON30460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30460.